43 related articles for article (PubMed ID: 19604123)
1. Therapies with emerging evidence of efficacy: avotermin for the improvement of scarring.
Bush J; So K; Mason T; Occleston NL; O'Kane S; Ferguson MW
Dermatol Res Pract; 2010; 2010():. PubMed ID: 20811604
[TBL] [Abstract][Full Text] [Related]
2. Development of antifibrotic therapy for stricturing Crohn's disease: lessons from randomized trials in other fibrotic diseases.
Lin SN; Mao R; Qian C; Bettenworth D; Wang J; Li J; Bruining DH; Jairath V; Feagan BG; Chen MH; ; Rieder F
Physiol Rev; 2022 Apr; 102(2):605-652. PubMed ID: 34569264
[TBL] [Abstract][Full Text] [Related]
3. The Burn Wound Microenvironment.
Rose LF; Chan RK
Adv Wound Care (New Rochelle); 2016 Mar; 5(3):106-118. PubMed ID: 26989577
[No Abstract] [Full Text] [Related]
4. The Use of Biologic Scaffolds in the Treatment of Chronic Nonhealing Wounds.
Turner NJ; Badylak SF
Adv Wound Care (New Rochelle); 2015 Aug; 4(8):490-500. PubMed ID: 26244105
[No Abstract] [Full Text] [Related]
5. Overview of surgical scar prevention and management.
Son D; Harijan A
J Korean Med Sci; 2014 Jun; 29(6):751-7. PubMed ID: 24932073
[TBL] [Abstract][Full Text] [Related]
6. TGF-β3 modulates the inflammatory environment and reduces scar formation following vocal fold mucosal injury in rats.
Chang Z; Kishimoto Y; Hasan A; Welham NV
Dis Model Mech; 2014 Jan; 7(1):83-91. PubMed ID: 24092879
[TBL] [Abstract][Full Text] [Related]
7. Skin wound healing modulation by macrophages.
Rodero MP; Khosrotehrani K
Int J Clin Exp Pathol; 2010 Jul; 3(7):643-53. PubMed ID: 20830235
[TBL] [Abstract][Full Text] [Related]
8. Prophylactic administration of avotermin for improvement of skin scarring: three double-blind, placebo-controlled, phase I/II studies.
Ferguson MW; Duncan J; Bond J; Bush J; Durani P; So K; Taylor L; Chantrey J; Mason T; James G; Laverty H; Occleston NL; Sattar A; Ludlow A; O'Kane S
Lancet; 2009 Apr; 373(9671):1264-74. PubMed ID: 19362676
[TBL] [Abstract][Full Text] [Related]
9. Avotermin for the improvement of scar appearance: a new pharmaceutical in a new therapeutic area.
Occleston NL; Fairlamb D; Hutchison J; O'Kane S; Ferguson MW
Expert Opin Investig Drugs; 2009 Aug; 18(8):1231-9. PubMed ID: 19604123
[TBL] [Abstract][Full Text] [Related]
10. Discovery and development of avotermin (recombinant human transforming growth factor beta 3): a new class of prophylactic therapeutic for the improvement of scarring.
Occleston NL; O'Kane S; Laverty HG; Cooper M; Fairlamb D; Mason T; Bush JA; Ferguson MW
Wound Repair Regen; 2011 Sep; 19 Suppl 1():s38-48. PubMed ID: 21793965
[TBL] [Abstract][Full Text] [Related]
11. Avotermin: a novel antiscarring agent.
Durani P; Occleston N; O'Kane S; Ferguson MW
Int J Low Extrem Wounds; 2008 Sep; 7(3):160-8. PubMed ID: 18757391
[TBL] [Abstract][Full Text] [Related]
12. Scar-free healing: from embryonic mechanisms to adult therapeutic intervention.
Ferguson MW; O'Kane S
Philos Trans R Soc Lond B Biol Sci; 2004 May; 359(1445):839-50. PubMed ID: 15293811
[TBL] [Abstract][Full Text] [Related]
13. New therapeutics for the prevention and reduction of scarring.
Occleston NL; O'Kane S; Goldspink N; Ferguson MW
Drug Discov Today; 2008 Nov; 13(21-22):973-81. PubMed ID: 18824245
[TBL] [Abstract][Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
